Signing Ceremony for Strategic Cooperation Between Gluetacs and Medicilon IND R&D Service

On January 1, 2021, Gluetacs and Shanghai Medicilon signed a strategic cooperation agreement in Medicilon Chuansha Park and reached a long-term strategic cooperative relationship. Former Director of the Institute of Organic Chemistry of the Chinese Academy of Sciences, former Vice President of the Shanghai Institute for Advanced Study, former Director of the Institute of Immunochemistry of Shanghai University of Science and Technology, Academician Jiang Biao, Director of the One Belt One Road Bangkok Center of the Chinese Academy of Sciences, Dr. Yang Xiaobao, General Manager of Gluetacs Biotech, National Science Research International Tong Yanhui, General Manager of Technology Transfer Co., Ltd., Pan Hong, Project General Manager, Dr. Chunlin Chen, Founder & CEO of Medicilon, Dr. Feng Ren, Senior Vice President of Chemistry & Biology, and Dr. Jinna Cai, Vice President of Commerce, attended the signing ceremony.

At the meeting, Dr. Chunlin Chen, Founder & CEO of Medicilon, first welcomed the visit of Gluetacs Biotech and his delegation, and expressed his expectation and confidence in the future cooperation between the two parties on behalf of Medicilon. Dr. Chunlin Chen reviewed the process of cooperation with Gluetacs Biotech and thanked the other party for their support to Medicilon’s R&D project along the way. At the same time, he introduced in detail the achievements of Medicilon's one-stop preclinical medicine R&D service platform. Regarding this cooperation, Dr. Chunlin Chen hopes to take this opportunity to form close exchanges between the two parties, realize long-term scientific research cooperation, and jointly promote new drugs. Research and development, strive to achieve the early launch of new drugs, and contribute to human health. As a company with 17 years of preclinical medicine R&D service outsourcing experience, Medicilon is committed to helping customers accelerate the development of new drugs with efficient and cost-effective R&D services, and promotes the progress of preclinical CRO with the company’s innovative development. Medicilon’s R&D services meet the current R&D outsourcing needs of Gluetacs Biotech. It is of great significance to accelerate the development and launch of new drugs by using their respective advantages to cooperate.

At the same time, academician Jiang Biao, director of the Chinese Academy of Sciences’ One Belt One Road Bangkok Center, delivered a speech, saying: I am very pleased to see that his old friend Chen Chunlin has led Medicilon on a rapid development path in recent years, helping China’s original innovative drugs move forward. Become a leader in the CRO field. As one of the founders of Gluetacs Bio, he also hopes to accelerate the speed and efficiency of Gluetacs’s research and development with the help of Medicilon, and develop a protein-degrading drug developed by the Chinese on the market as soon as possible. , For the benefit of the domestic people.

Dr. Yang Xiaobao, General Manager of Gluetacs, delivered a speech at the meeting, saying: I am honored to be invited to visit Medicilon Chuansha Park. I have a new understanding and understanding of Medicilon’s very professional new drug service team and its management team, and thus The need for cooperation between the two parties and the concept of win-win cooperation in the future have been strengthened. Through Chen Chunlin’s self-introduction and company introduction, I set an example for me, a young man who officially left the university on the first day of 2021 to enter the entrepreneurial road. With the help and advancement of Medicilon, I strengthened my own entrepreneurship and its goals. The original intention and determination to develop a protein degradation drug. In fact, before starting the business, Medicilon had already obtained high-quality service outsourcing from Medicilon, laying a solid foundation for future cooperation. Dr. Yang Xiaobao also expressed his hopes for the future development of the companies of both parties, wishing the cooperation between the two parties will achieve fruitful results. Subsequently, representatives of the two parties signed a strategic agreement, and the participants took a group photo together.

Representatives of Gluetacs Biotech and Medicilon signed a strategic agreement

Immediately afterwards, the heads of the various scientific research departments of Medicilon conducted project communication and explanations at the project kick-off meeting, and introduced in detail Medicilon’s series of services in compliance with international standards from drug discovery, pharmaceutical research, preclinical research to IND declaration . The two parties communicated and exchanged on the core issues of the project, reached a preliminary consensus, and ended the meeting in a pleasant atmosphere. Since 2015, Medicilon has participated in the research and development of 91 new drugs and generic drugs projects that have been approved by China NMPA/US FDA/Australia TGA/Sweden EMA to enter clinical research, and more than 700 domestic and foreign customers have cooperated. A wealth of practical cases and application experience will escort this cooperation and promote the smooth progress of the standard new biological project.

Gluetacs and Medicilon took a group photo together

Coincidentally, the meeting happened to be at 11:11 on January 1, 2021. The signing ceremony of Gluetacs and Medicilon ended, and the strategic cooperation was officially reached, bringing new ideas to the project at this special time on the first day of the new year. Meteorological new hope, hope this indicates the smooth progress of the project, Medicilon can help Gluetacs complete the dream of launching the first protein degradation drug on the market, and bring a new dawn to human health!

About Gluetacs

Gluetacs Therapeutics was established in 2020 and introduced the patented technology package of the PROTAD technology platform of Shanghai University of Science and Technology, dedicated to the development of tumor and immune-related therapies. The company’s technical feature is a dual-platform (Molecular Glue and PROTAC) strategic technical route with differentiation and intellectual property rights. The company was founded by academicians and their scientists who have been cultivating in the field of protein degradation for many years. It is guided by a team of experts in AI drug design from research institutes, DEL discovery platform, drug screening platform, proteomics platform, and tumor animal model platform. Process drug development process. The company is located in Building 6 of Shanghai Advanced Research Institute (Shanghai University of Science and Technology Incubator). The company has received tens of millions of RMB in angel rounds of financing for the promotion of IND candidates for molecular glue platforms and the development of PROTAC, a target in the oncology field, with the goal of solving clinical drug needs and benefiting patients.

About Medicilon

Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials. Pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!

contact us

Email: marketing@medicilon.com

Tel: +86 (21) 5859-1500